BeursBonobo schreef op 26 oktober 2017 15:55:
Exchange-traded funds that track the biotechnology sector sank on Thursday, following weak results from a major component. The iShares Nasdaq Biotechnology ETF IBB, -1.88% lost 2.5% and was on track for its seventh straight daily drop. The fund has declined by 4.3% over the past month, though it remains up 18.2% for 2017. The biggest weight on the sector on Thursday was Celgene Corp. CELG, -18.94% which plummeted 19% after the company reported better-than-expected profit, but failed to meet analysts' consensus estimates on revenue. The biotech company also lowered its 2017 outlook for profit and revenue. Among other big decliners, Gilead Sciences Inc. GILD, -0.75% fell 1.3%, BioMarin Pharmaceutical Inc. BMRN, -1.93% was off 1.8% and Regeneron Pharmaceuticals Inc. REGN, -0.84% was down 0.8%. The SPDR S&P Biotech ETF XBI, -0.95% lost 1.8%, on track for its eighth straight daily decline, as well as its 14th drop of the past 15 sessions.